Previous studies have reported that the combination of trastuzumab and pembrolizumab exhibits long-lasting clinical benefits in HER2+ BC, GEJC, GC, and esophageal cancers, reinforcing the hypothesis that upregulation of PD-L1 contributes to resistance to trastuzumab (20, 22). The gene discussed is ERBB2; the disease is esophageal cancer.